SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $20.00 by Analysts at Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS) had its target price decreased by Chardan Capital from $25.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $11.40.

SAB Biotherapeutics Stock Down 11.8 %

Shares of NASDAQ:SABS opened at $1.20 on Tuesday. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 12 month low of $1.11 and a 12 month high of $5.01. The firm’s 50-day moving average is $1.93 and its 200 day moving average is $2.82.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Friday, March 28th. The company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.12 million. As a group, sell-side analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors have recently modified their holdings of SABS. Kovitz Investment Group Partners LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $52,000. HB Wealth Management LLC raised its position in SAB Biotherapeutics by 118.6% during the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after purchasing an additional 128,800 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after buying an additional 12,692 shares during the period. Diadema Partners LP bought a new position in shares of SAB Biotherapeutics during the 4th quarter worth $114,000. Finally, Northern Trust Corp bought a new position in shares of SAB Biotherapeutics during the 4th quarter worth $43,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.